Associated Genetic Biomarkers
Nuclear receptor subfamily 4, group A, member 3 (NR4A3) is a gene that encodes a protein that functions as a transcriptional activator. Fusion mutations are observed in this gene.
NR4A3 is altered in 0.05% of all cancers with extraskeletal myxoid chondrosarcoma, lung adenocarcinoma, myxoid chondrosarcoma, astrocytoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations .
The most common alterations in NR4A3 are NR4A3-EWSR1 Fusion (0.04%), NR4A3 Fusion (0.02%), NR4A3 Q5P (0.02%), NR4A3 V4I (0.02%), and NR4A3 V4L (0.02%) .
NR4A3 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains NR4A3 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with NR4A3 status in the inclusion eligibility criteria most commonly target soft tissue sarcoma .
The most frequent alteration to serve as an inclusion eligibility criterion is NR4A3 Fusion .
Kb-0742 is the most frequent therapy in trials with NR4A3 as an inclusion criteria .
Significance of NR4A3 in Diseases
Soft Tissue Sarcoma +
Malignant Solid Tumor +
Non-Hodgkin Lymphoma +
NR4A3 is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NR4A3 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.